Palvella Therapeutics, Inc. (PVLA) Liabilities and Shareholders Equity (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed Liabilities and Shareholders Equity for 12 consecutive years, with $20.5 million as the latest value for Q3 2024.
- On a quarterly basis, Liabilities and Shareholders Equity fell 65.44% to $20.5 million in Q3 2024 year-over-year; TTM through Dec 2024 was $75.1 million, a 68.29% decrease, with the full-year FY2023 number at $7.5 million, down 92.1% from a year prior.
- Liabilities and Shareholders Equity was $20.5 million for Q3 2024 at Palvella Therapeutics, down from $25.1 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $164.2 million in Q3 2021 to a low of $7.5 million in Q4 2023.
- A 5-year average of $95.2 million and a median of $105.0 million in 2020 define the central range for Liabilities and Shareholders Equity.
- Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 46.23% in 2021, then tumbled 92.1% in 2023.
- Palvella Therapeutics' Liabilities and Shareholders Equity stood at $105.0 million in 2020, then surged by 46.23% to $153.6 million in 2021, then tumbled by 37.82% to $95.5 million in 2022, then crashed by 92.1% to $7.5 million in 2023, then skyrocketed by 171.89% to $20.5 million in 2024.
- Per Business Quant, the three most recent readings for PVLA's Liabilities and Shareholders Equity are $20.5 million (Q3 2024), $25.1 million (Q2 2024), and $29.5 million (Q1 2024).